Preclinical Medications Screening in Dependence, Affect and Pain Models of Alcoholism
This notice is related two Sources Sought Notices, NIH-NICHD-2018-05, released on 2/1/18 and 3/21/18. This acquisition is a full and open competition.
This notice is issued on behalf of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) by the National Institute of Child Health and Human Development (NICHD), Office of Acquisitions, NIH, DHHS. This is a Pre-solicitation Notice in advance of the Request for Proposals (RFP). The Government is not committed to award a contract pursuant to this announcement. The RFP, NIH-NICHD-2018-05, detailing the specifics of the project, as well as information pertinent to the development of an Offeror's proposal, will be available electronically within 15 calendar days of this notice and may be accessed through the Internet on the Federal Business Opportunities website: http://www.fedbizopps.gov. No paper solicitation is available. Potential Offerors are responsible for downloading the solicitation and for routinely checking the site for any solicitation amendments issued by the Government. Proposals will be due on June 22, 2018. It is anticipated that a single cost-reimbursement contract will be awarded for a period of five years (i.e. a one 12-month base period plus four (4) option periods) beginning on or about September 1, 2018.
This is a Research and Development contract requirement entitled, "Preclinical Medications Screening in Dependence, Affect and Pain Models of Alcoholism". This is NOT an NIH grant opportunity.
The NIAAA seeks a contractor to address the present and anticipated future needs of NIAAA's Medications Development Program. The Division of Neuroscience and Behavior's (DNB) Preclinical Medication Efficacy Testing Program seeks to support blind medication testing on alcohol drinking, and negative affect and pain measures, in the CIE model in rats. We wish to implement the testing capacity of four (4) compounds per year over the next five (5) years. The will use mechanisms having intellectual property conditions favorable to compound providers when acquiring compounds from industry. This will eliminate a major barrier to testing optimized compounds and will stimulate interest by the pharmaceutical industry in developing high quality, marketable compounds for alcoholism. The data generated will be used in the identification of compounds for further development.
All qualified organizations are encouraged to respond with a contract proposal.
Patricia N. Hanacek, Contract Specialist, Phone 301-594-6226, Fax 301-443-3891, Email hanacekp@mail.nih.gov - Jeremy D. White, Contracting Officer, Phone 301-402-4572, Email jeremy.white@nih.gov
